<DOC>
	<DOCNO>NCT00966043</DOCNO>
	<brief_summary>CYPTAM-BRUT 3 prospective , multicentric study Belgium within CYPTAM study Leiden University Medical Center ( NTR1509 ) include postmenopausal woman receive tamoxifen estrogen-receptor positive breast cancer adjuvant setting . The primary endpoint difference uterine change woman normal versus low TAS 3 month tamoxifen use . Secondary endpoint serum metabolite concentration , serum follicle-stimulating hormone level , serum sex hormone-binding globulin level menopausal symptom . These patient register Leiden protocol time breast cancer event primary endpoint .</brief_summary>
	<brief_title>Prevalence Genetic Polymorphisms Genes Coding Tamoxifen Metabolising Enzymes</brief_title>
	<detailed_description>We study impact 'tamoxifen activity score ' - base functional genetic polymorphism tamoxifen metabolism use drug interfere tamoxifen-against tamoxifen related endpoint like uterine change subjective menopausal symptom . The prevalence genetic polymorphism CYP2D6 gene difference usage drug interact tamoxifen metabolism compare woman without endometrial thicken one hand woman without hot flash hand . Tamoxifen use adjuvant setting . - `` Tamoxifen activity score '' ( 23 ) : The endpoint correlate predefined 'tamoxifen activity score ' base presence single nucleotide polymorphism ( SNP ) relevant gene combine effect well know drug interfere metabolism tamoxifen . The 'tamoxifen activity score ' associate tamoxifen compliance group US ( 23 ) . The score adapt Belgian situation base prevalence SNPs Belgian population volunteer blood donation consecutive breast cancer patient . - The study set postmenopausal woman early ER- positive breast cancer previously treat endocrine agent hormone replacement therapy , intact uterus clearly measurable thin endometrium/uterus . N =250</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Female &gt; 18 year age Written voluntary inform consent understood sign date Histologically cytologically confirm measurable invasive adenocarcinoma breast , amenable curative therapy . Patients must postmenopausal defined criterion appendix 1 . Breast cancer consider oestrogen receptor positive clinician use immunohistochemistry reading standard procedure local pathologist Prior endocrine tamoxifen therapy allow Patients previously treat endocrine agent hormone replacement therapy need stop least 6 month . Prior chemotherapy radiotherapy allow Adequate renal liver function Serum creatinine serum bilirubin ≤ 1.5 X ULN Serum ALT AST ≤ 2.5 X ULN ( ≤ 5 case liver metastasis ) Serum calcium ≤ 11,6 mg/dl ECOG performance status 0,1,2 ( appendix 2 ) Male Life threaten disease require quick response ( eg , extensive hepatic pulmonary involvement ) Use endocrine treatment recent/current use hormone replacement therapy . Contra indication tamoxifen : history DVT/vaginal bleeding unknown origin Dementia History malignancy may interfere least 6 month tamoxifen therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>